Stephen P Hunger, Thai Hoa Tran, Vaskar Saha, Meenakshi Devidas, Maria Grazia Valsecchi, Julie M Gastier-Foster, Giovanni Cazzaniga, Shalini C Reshmi, Michael J Borowitz, Anthony V Moorman, Nyla A Heerema, Andrew J Carroll, Patricia Martin-Regueira, Mignon L Loh, Elizabeth A Raetz, Kirk R Schultz, William B Slayton, Gunnar Cario, Martin Schrappe, Lewis B Silverman, Andrea Biondi
BACKGROUND: The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia. METHODS: CA180-372/COG AALL1122 was a joint Children's Oncology Group (COG) and European intergroup study of post-induction treatment of Ph-positive acute lymphoblastic leukaemia (EsPhALL) open-label, single-arm, phase 2 study...
July 2023: Lancet Haematology